334397
Impact of a pharmacy-based intervention to increase access to use non-occupational post-exposure prophylaxis for HIV prevention among a marginalized population in New York City: The iPEPcare study
Methods: Targeted street outreach, word-of-mouth, and pharmacy staff recruitment of syringe customers were used to recruit from high drug use neighborhoods (n=483). An educational PEP video was viewed and pre-/post-video surveys were conducted to assess PEP willingness. McNemar’s test was used to identify changes in willingness and log-binomial regression was used to determine correlates of (1) willingness to use PEP in general, and (2) willingness to initiate PEP acquired directly from a pharmacy, post-video.
Results: Among HIV-negative participants (n=410), willingness to use PEP increased significantly post-video (66.8% vs. 95.8%;p<0.0001). After adjustment, those who were willing to take PEP post-video were less likely to be employed (APR: 0.93; 95% CI: 0.87-0.99) and had lower external HIV stigma (APR: 0.99; 95% CI: 0.97-1.0). While willingness to initiate PEP acquired directly from a pharmacy post-video did not differ by correlates explored, the proportion willing to use a pharmacy for direct PEP access significantly increased between pre-, and post-video (76.6% vs. 96.4%;p<0.0001).
Conclusions: A structural intervention that uses pharmacies to provide PEP without an initial clinic visit may be effective in increasing PEP uptake among a high-risk NYC population.
Learning Areas:
EpidemiologyImplementation of health education strategies, interventions and programs
Learning Objectives:
Identify the impact of a pharmacy-based intervention that provides access to post-exposure prophylaxis (PEP) for HIV prevention on willingness to use PEP.
Keyword(s): HIV Interventions
Qualified on the content I am responsible for because: I was the project director of the study and several other pharmacy-based intervention studies.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.